000 | 05042cam a2200625 i 4500 | ||
---|---|---|---|
001 | on1178868370 | ||
003 | OCoLC | ||
005 | 20221128212722.0 | ||
006 | m d | ||
007 | cr ||||||||||| | ||
008 | 140708s2014 nyu ob 001 0 eng | ||
010 | _a 2020679602 | ||
040 |
_aDLC _beng _erda _cDLC _dN$T _dE7B _dYDXCP _dOCLCF _dEBLCP _dSAV _dSTF _dOCLCO _dOCLCA _dOCLCO |
||
019 |
_a890942048 _a914433448 _a923676305 _a928196009 _a992827141 |
||
020 |
_a9781633216013 _qebook |
||
020 | _a1633216012 | ||
020 |
_z1633215849 _qhbk. |
||
020 |
_z9781633215849 _qhbk. |
||
035 |
_a836693 _b(N$T) |
||
035 |
_a(OCoLC)1178868370 _z(OCoLC)890942048 _z(OCoLC)914433448 _z(OCoLC)923676305 _z(OCoLC)928196009 _z(OCoLC)992827141 |
||
042 | _apcc | ||
072 | 7 |
_aMED _x085000 _2bisacsh |
|
049 | _aMAIN | ||
245 | 0 | 0 |
_aMacular edema : _brisk factors, treatment options and long-term outcomes _c _h[E-Book] |
264 | 1 |
_aNew York : _bNova Publishers, _c[2014] |
|
300 | _a1 online resource. | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
490 | 1 | _aEye and Vision Research Developments | |
504 | _aIncludes bibliographical references and index. | ||
588 | _aDescription based on print version record and CIP data provided by publisher. | ||
505 | 0 | _aMACULAR EDEMA: RISK FACTORS, TREATMENT OPTIONS AND LONG-TERM OUTCOMES; MACULAR EDEMA: RISK FACTORS, TREATMENT OPTIONS AND LONG-TERM OUTCOMES; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: MANAGEMENT OF DIABETIC MACULAR EDEMA BY INTRAVITREAL ANTIANGIOGENIC DRUGS; ABSTRACT; INTRODUCTION; ROLE OF VEGF; PEGAPTANIB (MACUGEN�, PFIZER OPHTHALMICS); RANIBIZUMAB (LUCENTIS�, GENENTECH, NOVARTIS); BEVACIZUMAB (AVASTIN�, ROCHE, GENENTECH); AFLIBERCEPT (EYLEA�, BAYER, REGENERON PHARMACEUTICALS); TREATMENT PROTOCOLS; CONCLUSION; REFERENCES. | |
505 | 8 | _aChapter 2: MANAGEMENT OF MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION BY INTRAVITREAL BEVACIZUMABABSTRACT; INTRODUCTION; PATHOGENESIS; TREATMENT; ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR; ANTIANGIOGENIC TREATMENT; INTRAVITREOUS BEVACIZUMAB IN BRVO; INTRAVITREOUS BEVACIZUMAB IN CRVO; ANTI-VEGF IN ISCHEMIC RETINA; TREATMENT PROTOCOLS; CONCLUSION; REFERENCES; Chapter 3: POSTOPERATIVE CYSTOID MACULAR EDEMA IN DIABETIC PATIENTS: PROPHYLAXIS AND MANAGEMENT; ABSTRACT; INTRODUCTION; PATHOGENESIS; PREOPERATIVE CARE; MANAGEMENT; REFERENCES; Chapter 4: MANAGEMENT OF DIABETIC MACULAR EDEMA. | |
505 | 8 | _aABSTRACTINTRODUCTION; MANAGEMENT OF SYSTEMIC RISK FACTORS; LASER PHOTOCOAGULATION FOR DME; PHARMACOLOGICAL DME TREATMENT; COMBINATION THERAPY FOR DME MANAGEMENT; SURGICAL TREATMENT OF DME; TREATMENT GUIDELINES OF DME; CONCLUSION; REFERENCES; Chapter 5: CURRENT MANAGEMENT OF CHRONIC DIABETIC MACULAR OEDEMA; ABSTRACT; INTRODUCTION; EPIDEMIOLOGY OF DIABETIC MACULAR OEDEMA; PATHOPHYSIOLOGY OF CHRONIC DIABETIC MACULAR OEDEMA; INVESTIGATIONS FOR DMO; LASER TREATMENT IN THE MANAGEMENT OF CHRONIC DIABETIC MACULAR OEDEMA; ANTI-VEGF THERAPIES. | |
505 | 8 | _aINTRAVITREAL STEROIDS TO TREAT CHRONIC DIABETIC MACULAR OEDEMADMO TREATMENT ALGORITHM; FUTURE MANAGEMENT OPTIONS; CONCLUSION; REFERENCES; Chapter 6: MACULAR EDEMA IN IMPORTANT TROPICAL INFECTIONS; ABSTRACT; INTRODUCTION; MACULAR EDEMA IN SOME IMPORTANT TROPICAL INFECTIONS; CONCLUSION; REFERENCES; Chapter 7: CYSTOID MACULAR EDEMA: A DIFFICULT OCULAR DISORDER TO CURE; ABSTRACT; INTRODUCTION; MACULAR HOLE; TREATMENT OF MACULAR EDEMA; CASE REPORT; DISCUSSION; CONCLUSION; ACKNOWLEDGMENTS; REFERENCES; INDEX. | |
520 | _aMacular edema is a serious eye disorder that can be seen in many conditions. Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are frequent causes of decreased central visual acuity (VA) related to the appearance of macular edema (ME) and ischemia. This book discusses the risk factors, treatment options and long-term outcomes of macular edema. Some of the topics discussed include the management of diabetic macular edema; management of macular edema secondary to retinal vein occulsion by intravitreal bevacizumab; and macular edema in important tropical infections. | ||
590 | _aWorldCat record variable field(s) change: 650 | ||
650 | 0 |
_aMacula lutea _xDiseases. |
|
650 | 0 | _aEdema. | |
650 | 0 | _aMacula lutea. | |
650 | 0 |
_aEye _xDiseases. |
|
650 | 2 | _aMacula Lutea | |
650 | 2 | _aEdema | |
650 | 2 | _aEye Diseases | |
700 | 1 |
_aDavison, Earl, _eeditor. |
|
830 | 0 | _aEye and Vision Research Developments. | |
856 | 4 | 0 |
_uhttps://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=836693 _yKingston Hospital NHS Foundation Trust OpenAthens account holders click here for access |
938 |
_aProQuest Ebook Central _bEBLB _nEBL3024678 |
||
938 |
_aebrary _bEBRY _nebr10918995 |
||
938 |
_aEBSCOhost _bEBSC _n836693 |
||
938 |
_aYBP Library Services _bYANK _n11975933 |
||
942 | _n0 | ||
994 |
_a92 _bN$T |
||
999 |
_c91919 _d91919 |